Latest Patents News

Olympus Corporation has launched a nationwide emphysema screening campaign in the US powered by 4DMedical’s AI lung density analysis, marking a major commercial milestone for the Australian medtech firm.

IperionX has secured its first U.S. Army task order worth $1.3 million under a $99 million SBIR Phase III contract, marking a significant step in reshoring titanium production for U.S. defense needs.

Cyclopharm Limited has secured the maximum five-year U.S. patent extension for its flagship Technegas® Kit, extending market exclusivity to 2031 and reinforcing its strategic foothold in pulmonary imaging.

Proteomics International Laboratories has expanded its Share Purchase Plan offer after receiving applications exceeding $7.5 million, significantly increasing the number of new options issued.

IperionX has secured a significant U.S. Department of Defense contract worth up to US$99 million to supply low-cost, high-performance titanium components, marking a major step in reshoring critical materials manufacturing.

Anagenics Limited’s proprietary hair regrowth technology powers the newly launched Bouf Haircare brand, which has achieved over $500,000 in sales in its first week, setting the stage for a lucrative royalty stream.

Everest Metals Corporation has completed a breakthrough engineering study demonstrating 97% rubidium recovery at its Mt Edon project, advancing Australia’s entry into the global rubidium market with a patented extraction process.

INOVIQ Limited has revealed promising data for its EXO-OC™ ovarian cancer screening test, demonstrating exceptional accuracy and flawless detection of early-stage cancers. This innovation could transform early diagnosis and treatment outcomes for women worldwide.

Way2VAT Ltd has successfully raised A$2 million through a discounted share placement, aiming to bolster working capital and reduce short-term debt as it capitalises on recent client wins.

Metal Powder Works has doubled its production capacity for advanced metal powders using its patented DirectPowder™ process, achieving this milestone without additional capital expenditure. The company also cut production cycle times by up to 40%, positioning itself as a key US supplier for defence applications.

Nanoveu Limited has successfully completed the second tranche of its upsized capital raise, securing $720,000 through share issuance and listed options, with a final $400,000 tranche pending shareholder approval.

Amplia Therapeutics reports strong progress in its pancreatic cancer drug development, completing the ACCENT trial recruitment ahead of schedule and initiating a new US trial, while managing a $6.57 million loss for FY25.